跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
LUMYKRAS 240 MG COMPRIMIDOS RECUBIERTOS CON PELICULA - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
LUMYKRAS 240 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
Approved
STANDARD
LUMYKRAS 240 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
Amgen Europe B.V.
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
May 23, 2024
Approval ID
8d4c6b43c83db18f
Company
Amgen Europe B.V.
Type
Standard
Approval Details
Approval Id
8d4c6b43c83db18f
Drug Cima Aemps Name
LUMYKRAS 240 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
Register Number
1211603004
Holder Company Name
Amgen Europe B.V.
Marketing Company Name
Amgen S.A.
Holder Company Detail Path
/organization/amgen-europe-b-v
Marketing Company Detail Path
/organization/amgen-sa
Authorization Date
2024-05-23
Dosage Form
COMPRIMIDO RECUBIERTO CON PELÍCULA
Dose
240 mg
Route Of Administration
VÍA ORAL
Prescription Type
Diagnóstico Hospitalario
Commercialized
Yes
Company Name
Amgen Europe B.V.
Company Detail Path
/organization/amgen-europe-b-v
Company Information
Pharmaceutical Company Name
AMGEN EUROPE B.V.
Country Name
Israel
City Name
tel aviv-jaffa,central district,country_il
Address
Simtat Maoz
Active Ingredients
SOTORASIB
240 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
May 23, 2024
Approval ID
8d4c6b43c83db18f
Type
Standard
Back to CIMA-AEMPS Approvals
